Advertisement
Dr. Harmison stated: "I am very comfortable with our production linecapabilities in terms of their immediate capacity - which will now ramp up toa minimum of 125 production model Fidelity 100 devices per month and grow fromthere. This capability will be expanded significantly to meet growing demand.
Advertisement
The Company also added that it is continuing discussions with its Europeanand Asian partners (and prospective ones), and Dr. Harmison "anticipates thatthese opportunities will bear fruit ten days from today. I am pleased to beable to provide this update."
In finishing, Dr. Harmison stated: "The reach of the Frost & Sullivanorganization into Asia -and our devices having won the Frost technology awardsin two out of three years - has been a significant marketing tool whose usesare obvious and are compelling."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiovascular disease.
The Company has moved its corporate headquarters back to Los Angeles,California following the termination of prior management who desired theGreenville, South Carolina location and based their prospective success onthat location - which never came to fruition. The Company continues toconsult with several employees and professionals in the Greenville area.
Signalife is publicly traded on the American Stock Exchange under thesymbol SGN. The website for the company is http://www.Signalife.com. ClearData. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknownrisks, which may cause Signalife's actual results in the future to differmaterially from expected results. Factors which could cause or contribute tosuch differences include, but are not limited to, failure to complete thedevelopment and introduction of heart monitoring and other biomedical devicesincorporating Signalife's technology, failure to obtain federal or state orgovernmental or international regulatory approvals governing heart monitoringand other biomedical devices incorporating Signalife's technology, failure toobtain import and export capabilities in the various countries containingbuyers and resellers and hospitals and clinics and doctors for the Signalifedevices, inability to obtain physician, patient or insurance acceptance of forheart monitoring and other biomedical incorporating Signalife's technology,and the unavailability of financing to complete management's plans andobjectives, including the development of heart monitoring and other biomedicalincorporating Signalife's technology. These risks are qualified in theirentirety by cautionary language and risk factors set forth and to be furtherdescribed in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
